Vivos Therapeutics (VVOS) Change in Accured Expenses (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Change in Accured Expenses data on file, last reported at $385000.0 in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 185.56% year-over-year to $385000.0 in Q1 2026; TTM through Mar 2026 was $1.3 million, a 312.24% increase from a year earlier, with the FY2025 full-year figure at $483000.0, up 1338.46% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $385000.0, up from $168000.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for VVOS reached as high as $1.1 million in Q2 2025 and fell as low as -$538000.0 in Q3 2022.
• Historically, Change in Accured Expenses has averaged $59647.1 across 5 years, with a median of $9000.0 in 2023.
• On a YoY basis, Change in Accured Expenses climbed as much as 4000.0% in 2024 and fell as far as 3855.56% in 2024.
• Year by year, Change in Accured Expenses stood at $788000.0 in 2022, then sank by 100.13% to -$1000.0 in 2023, then slumped by 3700.0% to -$38000.0 in 2024, then soared by 542.11% to $168000.0 in 2025, then jumped by 129.17% to $385000.0 in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $385000.0 in Q1 2026, $168000.0 in Q4 2025, and -$331000.0 in Q3 2025.